TC Biopharm (Holdings) マネジメント

マネジメント基準チェック /34

TC Biopharm (Holdings)の CEO はBryan Kobelで、 Jun2021年に任命され、の在任期間は 3.33年です。の年間総報酬は£ 427.17Kで、 83.3%給与と16.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.44%を直接所有しており、その価値は€ 3.54K 。経営陣と取締役会の平均在任期間はそれぞれ3年と2.4年です。

主要情報

Bryan Kobel

最高経営責任者

UK£427.2k

報酬総額

CEO給与比率	83.3%
CEO在任期間	3.3yrs
CEOの所有権	0.4%
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	2.4yrs

経営陣の近況

Recent updates

CEO報酬分析

TC Biopharm (Holdings) の収益と比較して、Bryan Kobel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-UK£9m
Dec 31 2023	UK£427k	UK£356k	-UK£6m
Sep 30 2023	n/a	n/a	-UK£4m
Jun 30 2023	n/a	n/a	-UK£2m
Mar 31 2023	n/a	n/a	-UK£2m
Dec 31 2022	UK£436k	UK£363k	-UK£1m

報酬と市場: Bryanの総報酬 ($USD 553.61K ) は、 German市場 ($USD 486.57K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Bryanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Bryan Kobel (45 yo)

3.3yrs

在職期間

UK£427,169

報酬

Mr. Bryan Leland Kobel serves as Chief Executive Officer at TC Biopharm Limited. Mr. Kobel serves as Chief Executive Officer of TC Biopharm (Holdings) Plc since June 2021 and serves as Director. He joined...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Bryan Kobel	CEO & Director	3.3yrs	UK£427.17k	0.44% € 3.5k
Martin Thorp	CFO & Director	5.6yrs	UK£322.02k	0.00018% € 1.5
Christopher Camarra	Executive Vice President of Communications	2.8yrs	データなし	データなし
Lauren Bor	Head of Commercial Development Division	less than a year	データなし	データなし

3.0yrs

平均在職期間

経験豊富な経営陣: T0U0の経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Bryan Kobel	CEO & Director	no data	UK£427.17k	0.44% € 3.5k
Martin Thorp	CFO & Director	8.6yrs	UK£322.02k	0.00018% € 1.5
Arlene Morris	Non-Executive Independent Chair	2.7yrs	UK£23.53k	0% € 0
Mark Bonyhadi	Chairman of Scientific Advisory Board	2.4yrs	UK£23.53k	0% € 0
A. Culverwell	Non-Executive Independent Director	2.7yrs	UK£23.53k	0% € 0
Isabelle Riviere	Member of Scientific Advisory Board	2yrs	データなし	データなし
Daniel Olive	Member of Scientific Advisory Board	2yrs	データなし	データなし
Uma Lakshmipathy	Member of Scientific Advisory Board	2.4yrs	データなし	データなし
Erin Adams	Member of Scientific Advisory Board	2.4yrs	データなし	データなし
Blythe Sather	Member of Scientific Advisory Board	2yrs	データなし	データなし
Chris Bond	Member of Scientific Advisory Board	2yrs	データなし	データなし

2.4yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: T0U0の取締役会は経験豊富ではない ( 2.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

TC Biopharm (Holdings) マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

Recent updates

TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim

TC Biopharm (Holdings) Plc Announces Dosing of 5 New Patients in ACHIEVE

TC BioPharm (Holdings) PLC Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $2 million.

TC BioPharm (Holdings) PLC Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Provides Non-Compliance Update

TC Biopharm (Holdings) Plc Announces Launch of Compassionate Use Program for TCB008

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million.

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: UK£2.02 loss per share (vs UK£6.49 loss in FY 2021)

High number of new and inexperienced directors

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC Biopharm (Holdings) Plc Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc announced that it has received $7.35 million in funding

TC Biopharm (Holdings) Plc announced that it expects to receive $7.35 million in funding

Tc BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, Omnimmune(R), in Patients with Acute Myeloid Leukemia

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 14, 2022

TC Biopharm (Holdings) Plc Announces Additions to Scientific Advisory Board

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 01, 2022

TC Biopharm (Holdings) PLC Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $4 million.

TC Biopharm Announces Formation of Scientific Advisory Board

TC Biopharm (Holdings) Plc Receives CryoTC Trademark for Proprietary Cell Freezing Process

High number of new directors

TC Biopharm (Holdings) Plc Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

Insufficient new directors

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34